"Decision Resources" makes a Robust prediction

[willbb]

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical data and the opinions of interviewed thought leaders, telaprevir (Vertex’s Incivek, Johnson & Johnson’s Incivo) in combination with peg-IFNα (Roche’s Pegasys or Merck’s Victrelis) and ribavirin (Roche’s Copegus; Merck’s Rebetol; generics) has earned Decision Resources’ proprietary clinical gold standard status for the treatment of non-responder patients with hepatitis C virus (HCV). Owing to its competitive advantages in safety and tolerability as well as delivery, the interferon-free combination of Gilead’s GS-7977 (formerly PSI-7977) plus ribavirin will displace telaprevir plus peg-IFNα/ribavirin and earn proprietary clinical gold standard status for HCV non-responders in 2015, following its launch for the indication in 2014 in the United States.


http://finance.yahoo.com/news/2015-gilead-gs-7977-plus-140000214.html

[pooh55811]

Null Responder: A null responder is someone who achieves little or no decrease in hepatitis C viral load during HCV treatment. Null responders are highly unlikely to respond to re-treatment with an interferon-based regimen.

Non-responder: Often referred to as a "treatment failure," a non-responder is someone who does not have an EVR or, if they stay on treatment for 24 weeks, does not ever have a 2-log (99%) drop in hepatitis C viral load or undetectable HCV RNA during hepatitis C treatment.

Partial Responder: A partial responder is someone who experiences at least a 2-log decrease in hepatitis C viral load during HCV treatment. Partial responders are more likely to respond to re-treatment than non-responders or null responders.

Relapser: The term relapser refers to someone who has had an EVR or ETR, but whose virus rebounded after they completed HCV treatment. People who had a relapse after completing HCV treatment are more likely to achieve SVR after re-treatment than partial responders, non-responders, or null responders.

http://www.thebody.com/content/art46371.html

[slideman]

I cant remember the difference between non, and null responders. Could anybody clarify? Also is the new tx another PI therefor
anybody that has treated with a PI will not be able to tx with the int free tx?

[SusieS2010]

That is non-responders, not null-responders. We are still waiting.

[jules2551]

This is fantastic news!  At least they are still going in the right direction

Jules

[willbb]

Remember ..only a research teams prediction. and many things can throw  well intentioned predictions off the rails somewhat....however encouraging just the same..

Will

[stormy456]

Amazing news, Will!  2014 for interferon-free tx?  This news is going to make a lot of people happy.  ]